• Skip to primary navigation
  • Skip to main content
  • Skip to footer

Target ALS

A New York based ALS research organization that's leading the fight for a cure.

  • DONATE
  • About Us
    • Our Mission
    • Our Model
    • Our Impact
    • Our Founder
    • Our Team
    • Our Partners
  • For Scientists
    • Research Cores
      • Target ALS Data Engine
      • Longitudinal Biofluids Core
      • Human Postmortem Tissue Core
      • Stem Cell Core
      • Reagents Core
      • Animal Models Core
    • Funding Opportunities
    • Funded Projects
    • Annual Meeting
    • Science on Target Blog
  • Understanding ALS
    • About ALS
    • Understanding the Science
      • Glossary
      • FAQ
      • ALS 101
    • Voices of ALS
    • Video Library
  • Take Action
    • ALS Awareness Month:
      Behind the Breakthrough
    • Support Geoff Greulich
    • The ALS Global Research Initiative (AGRI)
      • Global Natural History Study
      • Community Based Pop-Up Clinics
    • Ways to Give
    • Email Sign Up
    • Contact Us
    • Donate Now
  • News
    • Announcements
    • In the News
    • Newsletters & Reports

Our Team

DANIEL L. DOCTOROFF

Having lost both his father and uncle to ALS, Daniel L. Doctoroff founded Target ALS in 2013 in collaboration with Bloomberg Philanthropies and financier and philanthropist David Rubenstein to create a new collaborative framework for scientists.

Mr. Doctoroff is currently the Founder and Chief Executive Officer of Sidewalk Labs, an Alphabet company that accelerates the integration of digital technology into urban environments. Prior to forming Sidewalk Labs, he was president and CEO of Bloomberg LP, the leading provider of financial news and information, and before that he was New York City’s longest-serving Deputy Mayor for Economic Development and Rebuilding.

Prior to serving as Deputy Mayor, he was a managing director at Oak Hill Capital Partners. He serves on the boards of the University of Chicago, United States Olympic Committee, Bloomberg Philanthropies, World Resources Institute, and Human Rights First. He is the Founder and Chairman of The Shed, New York’s newest cultural institution. He is the author of Greater Than Ever: New York’s Big Comeback.

“This is a devastating disease, and there’s been little hope for those diagnosed, including my father and uncle. Thanks to promising research of the past few years, we now have the opportunity to radically change the progression of the disease and improve people’s lives.”

– Daniel L. Doctoroff, Founder

Target ALS Team

We have built a team that brings together a unique mix of clinical, scientific, business, and philanthropic expertise.

Manish Raisinghani
Manish Raisinghani, M.B.B.S., Ph.D.
Chief Executive Officer
Connect on LinkedIn
Kenneth
Kenneth Devaney
Chief Operations Officer
Connect on LinkedIn
ALS researcher
Burhan Siddiqui
Accounting & Financial Systems Manager
Connect on LinkedIn

Foundation Advisors

Our Foundation Advisors guide the Target ALS administration in ensuring that we are following best-in-class scientific approaches in our work, and they keep us closely connected to the latest developments in the field.

Henderson
Chris Henderson, Ph.D.
Former Chief Scientific Officer,
Alltrna
Leonard Petrucelli, Ph.D.
Leonard Petrucelli, Ph.D.
Chief Scientific Advisor, Target ALS
Professor of Neuroscience, Mayo Clinic

Board Members

The Target ALS Board of Directors sets overall policy and provides guidance to the Foundation’s executive leadership team. To ensure we craft truly groundbreaking strategies to foster collaboration and accelerate drug discovery and development, we have recruited a renowned, passionate group of pioneering academic leaders, pharmaceutical and biotech executives, patients and their family members, and visionary philanthropists.

Dan Doctoroff
Daniel L. Doctoroff
Founder & Board Chair, Target ALS
Founder & Former CEO, Sidewalk Labs Former CEO, Bloomberg LP Former Deputy Mayor of Economic Development and Rebuilding for the City of New York
John
John Dunlop, Ph.D.
Former Chief Scientific Officer,
Aliada Therapeutics
Richard Hargreaves
Richard Hargreaves, Ph.D.
Corporate Vice President,
Bristol-Myers Squibb
female scientist
Carole Ho, M.D.
Chief Medical Officer & Head of Development,
Denali Therapeutics
Landis
Story Landis, Ph.D.
Former Director, NIH NINDS, Board Liaison, Independent Review Committee
Sarah Sheikh
Sarah I. Sheikh, BM BCh, MSc, MRCP
Senior Vice President, Neuroscience
Takeda
Stacie Weninger, Ph.D.
President and Venture Partner,
F-Prime Biomedical Research Initiative
Zach Hall, PhD
Zach Hall, Ph.D.
Former Director,
NIH NINDS

Independent Review Committee

To avoid Conflicts of Interest (COI), all board and committee members, as well as staff, abide by a comprehensive COI policy and are neither allowed to apply for, nor receive funding from, Target ALS. The committee is chaired by Robert Miller, Ph.D., George Washington University.

Dr. Robert Miller
Robert Miller, Ph.D.
Chair, Target ALS IRC
Vice Dean for Research & Academic Affairs, George Washington University
Michaek Ahlijanian
Michael Ahlijanian, Ph.D
Chief Scientific Officer,
Pinteon Therapeutics
Manzoor
Manzoor Bhat, Ph.D., M.S.
Vice Dean for Research (Interim), Professor and Chair,
UT Health Science Center, San Antonio
Moses Chao
Moses Chao, Ph.D.
Professor, Department of Neuroscience
and Physiology,
New York University
Biljana Djukic, Ph.D.
Translational Medicine and Early Development Lead, Neurology and Rare Diseases,
Sanofi
Lisa Ellerby
Lisa Ellerby, Ph.D.
Professor,
Buck Institute
Kurt
Kenneth Fischbeck, M.D.
NIH Distinguished Investigator,
NIH NINDS
Zaven
Zaven Kaprielian, Ph.D.
Chief Scientific Officer,
Remix Therapeutics
Jim Kupiec, M.D.
Chief Clinical Development Officer,
Cassava Sciences
Lynne Maquat, Ph.D.
Director, Center for RNA Biology,
University of Rochester Medical Center
Robert
Robert Mays, Ph.D.
Gere Meredith
Jere Meredith, Jr., Ph.D.
Senior Director, Head of Neurology Discovery,
Eisai Co, Ltd
Richard Hargreaves
Richard Olson, Ph.D.
Director, Small Molecule Drug Discovery,
Bristol Myers Squibb
MRao
Mahendra Rao, M.D., Ph.D.
Chief Executive Officer,
Implant Therapeutics
Ian
Ian Reynolds, Ph.D.
President,
YaghPenn Consulting
Tracy Saxton
Tracy Saxton, Ph.D.
Managing Director,
Saxton Biopharma Consulting, LLC
Eric
Eric Schaeffer, Ph.D.
President,
Schaeffer Biopharma Consulting
Holly Soares
Holly Soares, Ph.D.
Global Head Neuroscience and Rare Disease Biomarkers, VP
Roche
Ajay
Ajay Verma, M.D., Ph.D.
Frank
Frank Walsh, Ph.D.
Founder and Chief Executive Officer,
Ossianix
Andrew
Andrew Wood, Ph.D.
VP, Clinical Neuroimaging Research,
CHDI
Brad Friedman
Brad Friedman, Ph.D.
Senior Principal Scientist, Department of OMNI Bioinformatics,
Genentech, Inc.
Roche Alexander McCampbell
Alexander McCampbell, Ph.D.
Global Head of Neuroscience & Rare Diseases Research,
Roche
Sarah Kucenas
Sarah Kucenas, Ph.D
Professor of Biology, Cell Biology, and Neuroscience,
University of Virginia
Kelly Monk
Kelly Monk, Ph.D
Co-Director,
Vollum Institute
Volkan Granit
Volkan Granit, MD, MSc
Medical Director, Clinical Development,
Biohaven Pharmaceuticals
Stephen Zicha, Ph.D.
Neuroscience Search & Evaluation,
Eli Lilly & Co.

Conflict of Interest Committee

The Target ALS Conflict of Interest Committee ensures that the Independent Review Committee has no stake in projects selected and addresses any conflict of interest issues raised by the research community.

The committee is chaired by Zach Hall, Ph.D., Former Director of National Institute of Neurological Disorders and Stroke.

Dan Doctoroff
Daniel L. Doctoroff
Founder & Board Chair, Target ALS
Founder & Former CEO, Sidewalk Labs Former CEO, Bloomberg LP Former Deputy Mayor of Economic Development and Rebuilding for the City of New York
Dr. Robert Miller
Robert Miller, Ph.D.
Chair, Target ALS IRC
Vice Dean for Research & Academic Affairs, George Washington University
Zach Hall, PhD
Zach Hall, Ph.D.
Former Director,
NIH NINDS
James Treanor, Ph.D.
Board Member and Former CEO,
ADRx
Neil Shneider, M.D., Ph.D.
Director, Eleanor and Lou Gehrig ALS Center,
Columbia University

Footer

Target ALS
  • Donate
  • Contact
  • Financial Reports
  • Call For Proposals
  • Annual Meeting
  • Privacy Policy
  • Credits

Follow Us

guidestar

We are a 501(c)(3) public charity (EIN: 81-0756743), eligible to receive tax-deductible contributions that directly support our mission to break down barriers to ALS research to find effective treatments.

The Target ALS (TALS) website is intended for informational purposes only. Opinions expressed may not be that of TALS or its employees. For more information about our digital policies, click here.

© 2023 Target ALS Foundation, Inc.
Target ALS Foundation
244 Madison Avenue #1025
New York, NY 10016
(332) 333-4140
Steck Insights WordPress Consulting

Join us this ALS Awareness Month to discover the people, stories, and science accelerating progress in ALS research.

Name(Required)
Interests(Required)
Mark the options that best describe your interest in ALS